News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
42,046 Results
Type
Article (1611)
Company Profile (8)
Press Release (40427)
Section
Business (16994)
Career Advice (10)
Deals (2443)
Drug Delivery (1)
Drug Development (4182)
Employer Resources (1)
FDA (619)
Job Trends (1026)
News (23252)
Policy (1302)
Tag
2027 Pharm Country Standard (1)
Academia (90)
Accelerated approval (2)
Adcomms (1)
Allergies (8)
Alliances (1405)
ALS (15)
Alzheimer's disease (96)
Antibody-drug conjugate (ADC) (23)
Approvals (694)
Artificial intelligence (17)
Autoimmune disease (22)
Bankruptcy (15)
Best Places to Work (1031)
Biosimilars (4)
Biotechnology (7)
Bladder cancer (29)
Brain cancer (1)
Breast cancer (59)
Cancer (434)
Cardiovascular disease (31)
Career advice (10)
CAR-T (20)
Cell therapy (45)
Clinical research (3927)
Collaboration (60)
Company closure (1)
Compensation (22)
Complete response letters (2)
COVID-19 (93)
CRISPR (5)
C-suite (8)
Cystic fibrosis (7)
Data (631)
Depression (9)
Diabetes (27)
Diagnostics (417)
Digital health (2)
Drug discovery (15)
Drug pricing (1)
Duchenne muscular dystrophy (17)
Earnings (15777)
Employer resources (1)
Events (7317)
Executive appointments (8)
FDA (1007)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (51)
Gene editing (6)
Generative AI (2)
Gene therapy (23)
GLP-1 (44)
Government (136)
Grass and pollen (2)
Guidances (165)
Healthcare (1087)
HIV (2)
IgA nephropathy (7)
Immunology and inflammation (12)
Immuno-oncology (3)
Indications (9)
Infectious disease (105)
Inflammatory bowel disease (18)
Influenza (6)
Intellectual property (9)
Interviews (1)
IPO (1859)
IRA (1)
Job creations (57)
Job search strategy (10)
JPM (6)
Labor market (1)
Layoffs (12)
Legal (164)
Liver cancer (5)
Longevity (2)
Lung cancer (61)
Lymphoma (47)
Manufacturing (13)
MASH (17)
Medical device (844)
Medtech (848)
Mergers & acquisitions (625)
Metabolic disorders (83)
Multiple sclerosis (13)
NASH (1)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (180)
NextGen: Class of 2026 (224)
Non-profit (82)
Obesity (36)
Opinion (1)
Ovarian cancer (11)
Pain (13)
Pancreatic cancer (26)
Parkinson's disease (13)
Patents (14)
Patient recruitment (16)
Peanut (1)
People (1135)
Pharmacy benefit managers (1)
Phase 1 (978)
Phase 2 (1648)
Phase 3 (1670)
Pipeline (852)
Policy (4)
Postmarket research (124)
Preclinical (399)
Press Release (1)
Prostate cancer (24)
Psychedelics (3)
Radiopharmaceuticals (15)
Rare diseases (43)
Real estate (142)
Recruiting (1)
Regulatory (1303)
Reports (1)
Research institute (58)
Resumes & cover letters (1)
RSV (3)
Schizophrenia (19)
Series A (6)
Series B (4)
Service/supplier (1)
Sickle cell disease (4)
Spinal muscular atrophy (5)
Startups (100)
Tariffs (1)
Vaccines (39)
Venture capital (4)
Weight loss (22)
Women's health (6)
Date
Today (1)
Last 7 days (43)
Last 30 days (168)
Last 365 days (2704)
2026 (271)
2025 (2714)
2024 (2766)
2023 (3093)
2022 (4192)
2021 (3742)
2020 (2972)
2019 (2402)
2018 (1667)
2017 (1275)
2016 (985)
2015 (1420)
2014 (972)
2013 (605)
2012 (797)
2011 (832)
2010 (773)
Location
Africa (21)
Alabama (5)
Arizona (18)
Asia (2580)
Australia (286)
California (1000)
Canada (247)
China (141)
Colorado (52)
Connecticut (49)
Delaware (39)
Europe (5219)
Florida (137)
Georgia (35)
Idaho (3)
Illinois (74)
India (4)
Indiana (54)
Japan (73)
Kansas (15)
Kentucky (2)
Louisiana (6)
Maine (11)
Maryland (102)
Massachusetts (633)
Michigan (28)
Minnesota (59)
Missouri (10)
Montana (3)
Nevada (9)
New Hampshire (5)
New Jersey (346)
New York (265)
North Carolina (144)
Northern California (531)
Ohio (22)
Oklahoma (2)
Pennsylvania (208)
Puerto Rico (3)
South America (28)
South Carolina (1)
Southern California (385)
Tennessee (6)
Texas (100)
United States (3474)
Utah (33)
Virginia (13)
Washington D.C. (3)
Washington State (74)
Wisconsin (12)
42,046 Results for "103".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Denovo Biopharma Announces Partnership with Orygen on Phase 2 Study Evaluating DB103 (Pomaglumetad Methionil) in Treating Psychosis
February 11, 2026
·
3 min read
Press Releases
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
February 10, 2026
·
5 min read
Press Releases
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
February 4, 2026
·
4 min read
Press Releases
Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases
January 12, 2026
·
4 min read
Press Releases
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
January 13, 2026
·
9 min read
Press Releases
Enspire DBS Therapy Announces $10.3 Million Series B1 Financing to Advance Pivotal Development of DBS-Enabled Stroke Rehabilitation
January 14, 2026
·
3 min read
Press Releases
Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103
February 5, 2026
·
5 min read
Press Releases
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 16, 2026
·
7 min read
Press Releases
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
December 9, 2025
·
8 min read
Press Releases
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
November 6, 2025
·
2 min read
1 of 4,205
Next
